

# Contents

## 1 Epidemiological Considerations in Breast Cancer

|       |  |   |
|-------|--|---|
| 1.1   | Introduction . . . . .   | 1 |
| 1.2   | Geographical Influences . . . . .  | 1 |
| 1.3   | Radiation as an Etiologic Agent . . . . .  | 2 |
| 1.4   | Electromagnetic Fields . . . . .   | 2 |
| 1.5   | Environmental Pollutants . . . . .   | 3 |
| 1.6   | Reproductive Factors . . . . .   | 3 |
| 1.7   | Environmental Exposures at a Young Age that Increase the Risk of Breast Cancer . . . . . | 4 |
| 1.7.1 | Endocrinological Milieu . . . . .  | 4 |
| 1.7.2 | Smoking . . . . .  | 4 |
| 1.7.3 | Alcohol as a Neuroendocrine Disruptor . . . . .  | 5 |
| 1.7.4 | Effect of Light on Puberty and Breast Cancer Risk . . . . .                              | 5 |
| 1.8   | Conclusions . . . . .  | 6 |
|       | References . . . . .   | 6 |

## 2 The Breast as a Developing Organ

|     |  |    |
|-----|--|----|
| 2.1 | Introduction . . . . .   | 11 |
| 2.2 | Prenatal and Perinatal Development . . . . .                                       | 12 |
| 2.3 | Postnatal Development . . . . .  | 15 |
| 2.4 | Pregnancy . . . . .  | 22 |
| 2.5 | Postlactational Changes . . . . .  | 26 |
| 2.6 | The Menopausal Breast . . . . .  | 26 |
| 2.7 | Parenchyma-Stroma Relationship . . . . .   | 29 |
| 2.8 | Genetic Influences in Breast Development . . . . .                                 | 30 |
| 2.9 | Cell Proliferation and Hormone Receptors in Relation to Breast Structure . . . . . | 31 |

|        |   |    |
|--------|---|----|
| 2.10   | Extracellular Matrix Protein Expression in the Normal Breast . . . . .                      | 32 |
| 2.10.1 | Angiogenic Index in the Lobular Structures . . . . .  | 32 |
| 2.10.2 | Elastin in the Lobular Structures . . . . .   | 34 |
| 2.10.3 | Tenascin in the Lobular Structures . . . . .  | 35 |
| 2.11   | Genomic Profile of Lobular Structures in Nulliparous and Parous Women's Breasts . . . . .   | 36 |
| 2.12   | Novel Differentiation-Associated Serpin is Upregulated During Lobular Development . . . . . | 40 |
| 2.13   | Mammary-Derived Growth Inhibitor . . . . .  | 45 |
| 2.14   | Conclusions . . . . .   | 45 |
|        | References . . . . .  | 46 |

## 3 Endocrine Control of Breast Development

|       |   |    |
|-------|---|----|
| 3.1   | Introduction . . . . .  | 49 |
| 3.2   | Steroid Receptors, Cell Proliferation, and Breast Differentiation . . . . .   | 51 |
| 3.2.1 | Relationship of Proliferating and ER $\alpha$ -Positive Cells in the Human Breast . . . . .                           | 53 |
| 3.2.2 | Cell Proliferation, ER $\alpha$ , and PgR Content in the Rat Mammary Gland . . . . .                                  | 53 |
| 3.2.3 | Biological Significance . . . . .   | 55 |
| 3.3   | Human Chorionic Gonadotropin as a Differentiating Agent in the Human Breast and in the Rodent Mammary Gland . . . . . | 57 |

|            |  |    |         |   |     |
|------------|--|----|---------|---|-----|
| 3.3.1      | Evidence for a Receptor for Human Chorionic Gonadotropin in Human Breast Epithelial Cells . . . . .                        | 57 | 4.3     | Role of Estrogens in Human Breast Proliferation . . . . .   | 94  |
| 3.3.2      | Human Chorionic Gonadotropin Receptor in the Rat Mammary Gland . . . . .   | 60 | 4.4     | Estrogens in Human Breast Carcinogenesis . . . . .  | 95  |
| 3.3.3      | Biological Significance of the LH/hCG Receptor . . . . .   | 60 | 4.4.1   | Receptor-Mediated Pathway . . . . .   | 96  |
| 3.4        | Effect of Human Chorionic Gonadotropin on Human Breast Epithelial Cells . . . . .  | 61 | 4.4.2   | Oxidative Metabolism of Estrogen . . . . .  | 98  |
| 3.4.1      | Effect on Protein Synthesis and In Vitro Translational Products of mRNA . . . . .  | 61 | 4.4.2.1 | Estrogen as Mutagenic Agents . . . . .  | 100 |
| 3.4.2      | Effect of Human Chorionic Gonadotropin Treatment on Inhibin Synthesis . . . . .  | 64 | 4.4.2.2 | The Mechanism by Which Estrogens Induce Mutations . . . . .   | 100 |
| 3.4.3      | Effect of Hormones on the Proliferative Activity of Cultured Normal and Neoplastic Human Breast Epithelial Cells . . . . . | 68 | 4.4.2.3 | Additional Factors Contributing to the Carcinogenic Effect of Estrogen . . . . .  | 100 |
| 3.4.4      | Biological Significance of the hCG-Inhibin Pathway . . . . .   | 69 | 4.4.3   | Estrogens as Inducers of Aneuploidy . . . . .   | 101 |
| 3.5        | Homeobox Genes' Expression and Their Modulation by Human Chorionic Gonadotropin in Human Breast Epithelial Cells . . . . . | 71 | 4.5     | Biological Demonstration That Estrogens Are Carcinogenic in the Human Breast . . . . .  | 102 |
| 3.5.1      | Class I Homeobox Gene Expression in Human Breast Epithelial Cell Lines . . . . .   | 72 | 4.5.1   | The Proof of Principle . . . . .  | 102 |
| 3.5.2      | Human Chorionic Gonadotropin Modulates Expression of Homeobox Genes . . . . .  | 73 | 4.5.2   | The In Vitro Model of Cell Transformation . . . . .   | 102 |
| 3.5.3      | Human Chorionic Gonadotropin and HOXA2 Inhibit AP-1 . . . . .  | 74 | 4.5.2.1 | Transformation Effect of Estrogen in MCF-10F Cells . . . . .  | 102 |
| 3.6        | Human Chorionic Gonadotropin and Histone Acetylation . . . . .   | 78 | 4.5.2.2 | Transformation Effect of the Estrogen Metabolites . . . . .   | 106 |
| 3.7        | Conclusions . . . . .  | 80 | 4.5.2.3 | Role of Antiestrogens in the Expression of the Transformation Phenotype . . . . .   | 109 |
| References | . . . . .  | 81 | 4.5.2.4 | Detection of Estrogen Receptors in MCF 10F-Cells . . . . .  | 111 |
|            |  |    | 4.5.2.5 | Evidence for a Role of ER $\beta$ and Metabolic Activation of Estrogen in the Transformation of Human Breast Epithelial Cells . . . . . | 112 |
|            |  |    | 4.5.3   | Genomic Changes Induced by Estrogen and Its Metabolites in Human Breast Epithelial Cells . . . . .                                      | 113 |
|            |  |    | 4.5.4   | Other Genomic Changes Induced by Estrogen and Its Metabolites in the Transformation of Human Breast Epithelial Cells . . . . .          | 118 |
|            |  |    | 4.5.5   | Chromosomal Alterations Induced by Estrogen and Its Metabolites . . . . .   | 124 |
| <b>4</b>   | <b>The Role of Estrogen in Breast Cancer</b>   |    |         |   |     |
| 4.1        | Introduction . . . . .   | 89 |         |   |     |
| 4.2        | Sources of Estrogens in Human Breast Tissue . . . . .  | 90 |         |   |     |

|     |  |     |
|-----|--|-----|
| 4.6 | A Unified Concept in the Role of Estrogen in Breast Cancer . . . . . | 128 |
|     | References . . . . .   | 128 |

## 5 Pathogenesis of Breast Cancer

|       |  |     |
|-------|--|-----|
| 5.1   | Introduction . . . . .   | 137 |
| 5.2   | The Site of Origin of Breast Cancer . . . . .  | 137 |
| 5.3   | Supporting Evidence for the Site of Origin of Breast Cancer . . . . .  | 139 |
| 5.3.1 | In Vitro Studies . . . . .   | 139 |
| 5.3.2 | Breast Architecture as a Determining Factor in the Susceptibility of the Human Breast to Cancer . . . . .  | 142 |
| 5.3.3 | Specific Considerations on the Relation Between Lobular Development and Familial Breast Cancer-Related Genes . . . . .   | 147 |
| 5.3.4 | Unifying Concepts . . . . .  | 149 |
| 5.4   | Molecular Changes in the Initiation and Progression of Breast Cancer . . . . .   | 150 |
| 5.4.1 | Differential Expression of Human Ferritin H Chain Gene and Breast Cancer . . . . .   | 150 |
| 5.4.2 | S100P Calcium-Binding Protein as a Marker of Cancer Initiation . . . . .   | 153 |
| 5.4.3 | Role of Intracellular $Ca^{2+}$ During Cell Immortalization and Cell Transformation . . . . .  | 161 |
| 5.4.4 | The Role of Ca Intracellular and S100 Protein Expression in the Formation of Microcalcifications in Preneoplastic and Neoplastic Lesions of the Breast . . . . . | 164 |
| 5.5   | Genetic Changes Associated with Initiation and Progression of Breast Cancer . . . . .  | 167 |
| 5.5.1 | Laser Capture Microdissection . . . . .  | 168 |
| 5.5.2 | Microsatellite Instability and Loss of Heterozygosity in Microdissected Lesions of the Breast . . . . .  | 171 |

|       |  |     |
|-------|--|-----|
| 5.5.3 | Example of Breast Cancer Genetic Heterogeneity Revealed by Laser Capture Microdissection Technique . . . . . | 172 |
|-------|--|-----|

|     |                                   |     |
|-----|-----------------------------------|-----|
| 5.6 | Summary and Conclusions . . . . . | 175 |
|     | References . . . . .              | 176 |

## 6 Animal Models for Human Breast Cancer

|         |   |     |
|---------|---|-----|
| 6.1     | Introduction . . . . .  | 181 |
| 6.2     | General Concepts . . . . .  | 181 |
| 6.3     | Chemically-Induced Mammary Tumorigenesis . . . . .                              | 182 |
| 6.4     | Radiation-Induced Mammary Tumorigenesis . . . . .                               | 183 |
| 6.5     | Genetic Background and Mammary Carcinogenesis . . . . .                         | 185 |
| 6.6     | Pathogenesis of Rat Mammary Tumors . . . . .                                    | 185 |
| 6.7     | Mammary Gland Differentiation as a Modulator of Carcinogenic Response . . . . . | 191 |
| 6.7.1   | Cell of Origin of Rat Mammary Carcinomas . . . . .                              | 195 |
| 6.7.2   | Cell Kinetics and Mammary Carcinogenesis . . . . .                              | 199 |
| 6.7.3   | Role of the Stroma in the Pathogenesis of Mammary Cancer . . . . .              | 204 |
| 6.8     | Pathological Classification of Rat Mammary Tumors . . . . .                     | 209 |
| 6.8.1   | Epithelial Neoplasms . . . . .  | 210 |
| 6.8.1.1 | Intraductal Papilloma . . . . .   | 210 |
| 6.8.1.2 | Papillary Cystadenoma . . . . .   | 210 |
| 6.8.1.3 | Adenoma . . . . .   | 210 |
| 6.8.1.4 | Precancerous Lesions: Intraductal Proliferation . . . . .                       | 210 |
| 6.8.1.5 | Carcinoma In Situ . . . . .   | 212 |
| 6.8.1.6 | Invasive Ductal Carcinomas . . . . .  | 212 |
| 6.8.2   | Stromal Neoplasms . . . . .   | 216 |
| 6.8.2.1 | Fibroma . . . . .   | 216 |
| 6.8.2.2 | Fibrosarcoma . . . . .  | 216 |
| 6.8.3   | Epithelial-Stromal Neoplasms . . . . .  | 217 |
| 6.8.3.1 | Fibroadenoma . . . . .  | 217 |
| 6.8.3.2 | Carcinosarcoma . . . . .  | 218 |
| 6.8.4   | Nonneoplastic Lesions . . . . .   | 218 |

|        |  |     |
|--------|--|-----|
| 6.9    | Differential Diagnosis of Mammary Tumors . . . . .   | 218 |
| 6.9.1  | Macroscopic Criteria . . . . .   | 220 |
| 6.9.2  | Histopathological Criteria . . . . .   | 220 |
| 6.9.3  | Biological Criteria . . . . .  | 220 |
| 6.10   | Biological Importance of the Chemical Carcinogen-Induced Rat Mammary Tumor Model . . . . . | 220 |
| 6.11   | Genetically Engineered Mice Model . . . . .  | 221 |
| 6.11.1 | Anatomy of the Mouse Mammary Gland . . . . .   | 221 |
| 6.11.2 | Classification of Genetically Engineered Mouse Mammary Lesions . . . . .                   | 224 |
| 6.11.3 | Comparative Pathology of the Model Systems . . . . .                                       | 224 |
|        | References . . . . .   | 225 |

## 7 In Vitro Models for Human Breast Cancer

|       |   |     |
|-------|---|-----|
| 7.1   | Introduction . . . . .  | 227 |
| 7.2   | Growth Properties of Normal Human Breast Epithelial Cells In Vitro . . . . .                            | 227 |
| 7.3   | The MCF-7 Cell as a Model of Human Breast Cancer In Vitro . . . . .                                     | 230 |
| 7.3.1 | Morphological and Growth Characteristics of MCF-7 Cells . . . . .                                       | 230 |
| 7.3.2 | Growth of MCF-7 Cells in Tridimensional Matrix . . . . .  | 233 |
| 7.3.3 | Growth of MCF-7 Cells in Athymic Mice . . . . .   | 237 |
| 7.4   | Growth Properties of Immortal Human Breast Epithelial Cells In Vitro . . . . .                          | 241 |
| 7.4.1 | Telomerase Activation . . . . .   | 243 |
| 7.4.2 | Abrogation of Cell Cycle Control . . . . .  | 243 |
| 7.4.3 | Genes Preferentially Expressed During Cell Immortalization . . . . .                                    | 247 |
| 7.5   | Transformation of Primary Cultures of Human Breast Epithelial Cells with Chemical Carcinogens . . . . . | 250 |
| 7.6   | In Vitro System of Cell Transformation . . . . .  | 252 |
| 7.6.1 | Transformation of Human Breast Epithelial Cells with c-Ha-ras Oncogene . . . . .                        | 252 |

|       |   |     |
|-------|---|-----|
| 7.6.2 | Transformation of Human Breast Epithelial Cells with Chemical Carcinogens . . . . .                     | 261 |
| 7.6.3 | Ha-ras Enhances the Transformation of Human Breast Epithelial Cells with Chemical Carcinogens . . . . . | 269 |
|       | References . . . . .  | 273 |

## 8 Genomic Basis of Breast Cancer

|         |  |     |
|---------|--|-----|
| 8.1     | Introduction . . . . .   | 281 |
| 8.2     | Genomic Changes Observed in Breast Cancer . . . . .  | 281 |
| 8.3     | Microsatellite Instability as an Early Genomic Event in Breast Cancer Initiation . . . . .         | 284 |
| 8.4     | Other Genomic Changes Associated with Immortalization, Transformation, and Tumorigenesis . . . . . | 288 |
| 8.4.1   | Tumor Suppressor Gene p53 . . . . .  | 288 |
| 8.4.2   | Oncogenes . . . . .  | 289 |
| 8.4.2.1 | c-Ha-ras . . . . .   | 289 |
| 8.4.2.2 | c-neu, int-2, and c-myc Oncogenes . . . . .  | 289 |
| 8.4.3   | mdm2 Gene . . . . .  | 290 |
| 8.4.4   | Loss of Heterozygosity and Fluorescence In Situ Hybridization Analysis of Chromosome 17p . . . . . | 291 |
| 8.5     | Search for Specific Functional Relevance of the Genomic Changes . . . . .                          | 292 |
| 8.5.1   | Reversion of the Immortalization Phenotype . . . . .   | 292 |
| 8.5.2   | Reversion of the Transformation but Not Immortalization Phenotype . . . . .                        | 302 |
| 8.6     | The Role of Mismatch Repair in the Initial Event of Carcinogenesis . . . . .                       | 307 |
| 8.7     | Unifying Concepts . . . . .  | 310 |
|         | References . . . . .   | 311 |

## 9 Preventive Strategies in Breast Cancer

|         |  |     |
|---------|--|-----|
| 9.1     | Introduction . . . . .                                       | 317 |
| 9.2     | Physicoprevention with Prophylactic Mastectomy . . . . .     | 320 |
| 9.3     | Bioprevention of Hereditary Breast Cancer . . . . .          | 320 |
| 9.4     | Chemoprevention Against Acquired Somatic Mutations . . . . . | 321 |
| 9.4.1   | Limiting Accumulation of Chemical Carcinogens . . . . .      | 323 |
| 9.4.2   | Enhancing Excretion of Xenobiotics . . . . .                 | 324 |
| 9.4.2.1 | Organosulfur Compounds . . . . .                             | 324 |
| 9.4.2.2 | Indole-3-Carbinol . . . . .                                  | 326 |
| 9.4.2.3 | Phytoalexin . . . . .  | 327 |
| 9.4.2.4 | Triterpenoids . . . . .                                      | 328 |
| 9.4.3   | Eliminating Oxidative Stress . . . . .                       | 328 |
| 9.4.3.1 | Carotenoids . . . . .  | 328 |
| 9.4.3.2 | Vitamin E and Selenium . . . . .                             | 330 |
| 9.4.3.3 | Tea and Polyphenolic Antioxidants . . . . .                  | 332 |
| 9.4.3.4 | Flavonoids . . . . .   | 333 |
| 9.5     | Chemoprevention Against Epigenetic Alterations . . . . .     | 335 |
| 9.5.1   | Restricting Fat/Caloric Consumption . . . . .                | 335 |
| 9.5.2   | Maintaining Proper Endocrine Milieu . . . . .                | 336 |
| 9.5.2.1 | Steroids . . . . .   | 336 |
| 9.5.2.2 | Aromatase Inhibitors . . . . .                               | 338 |
| 9.5.2.3 | Estrone Sulfatase Inhibitors . . . . .                       | 339 |
| 9.5.2.4 | Dehydroepiandrosterone . . . . .                             | 340 |
| 9.5.2.5 | Genistein . . . . .  | 340 |
| 9.6     | Melatonin . . . . .  | 341 |
| 9.7     | Eicosanoids . . . . .  | 343 |
| 9.8     | Estrogen Antagonists . . . . .                               | 345 |
| 9.8.1   | Antiestrogens . . . . .                                      | 345 |
| 9.8.2   | Aryl Hydrocarbon Receptor Agonists . . . . .                 | 346 |
| 9.9     | Interrupting Carcinogenic Signal Transduction . . . . .      | 347 |

|        |   |     |
|--------|---|-----|
| 9.9.1  | Inhibitors of Receptor Tyrosine Kinases . . . . .   | 347 |
| 9.9.2  | Inhibitors of p21 <sup>ras</sup> Farnesylation . . . . .  | 350 |
| 9.9.3  | Inhibitors of HMG-CoA Reductase . . . . .   | 351 |
| 9.9.4  | Monoterpenes . . . . .  | 351 |
| 9.9.5  | Eicosapentaenoic Acid . . . . .   | 352 |
| 9.10   | Inducing Breast Cell Differentiation . . . . .  | 352 |
| 9.10.1 | Retinoids . . . . .   | 352 |
| 9.10.2 | Pregnancy and Human Chorionic Gonadotropin . . . . .  | 354 |
| 9.11   | N-Chemoprevention Against Growth of Neoplasms: Suppressing the Growth of Neoplastic Cells . . . . . | 354 |
| 9.11.1 | Vitamin D and Calcium . . . . .   | 354 |
| 9.11.2 | Ornithine Decarboxylase Inhibitors . . . . .  | 356 |
| 9.12   | O-Inhibiting Neovascularization or Angiogenesis . . . . .   | 358 |
| 9.13   | Socioprevention of Breast Cancer . . . . .  | 358 |
| 9.14   | Summary and Future Perspectives . . . . .   | 359 |
|        | References . . . . .  | 360 |

## 10 The New Paradigm in Breast Cancer Prevention

|        |   |     |
|--------|---|-----|
| 10.1   | Rationale for a New Paradigm . . . . .  | 379 |
| 10.2   | The New Paradigm . . . . .  | 379 |
| 10.3   | Epidemiological and Clinical Basis for the New Paradigm . . . . .   | 380 |
| 10.4   | Data from Experimental Animal Studies . . . . .   | 381 |
| 10.4.1 | Pregnancy . . . . .   | 381 |
| 10.4.2 | Placental Hormones . . . . .  | 382 |
| 10.4.3 | Estrogenic and Progestagenic Agents . . . . .   | 385 |
| 10.4.4 | Role of Pregnancy and Chorionic Gonadotropin in Mammary Gland Differentiation and Cancer Initiation . . . . . | 387 |
| 10.5   | Role of Human Chorionic Gonadotropin in Breast Cancer Progression . . . . .                                   | 392 |
| 10.5.1 | Mammary Gland Development Under Influence of Human Chorionic Gonadotropin . . . . .                           | 393 |

|        |   |     |
|--------|---|-----|
| 10.5.2 | Hormonal Profile Induced by Human Chorionic Gonadotropin . . . . .  | 396 |
| 10.5.3 | Effect of Human Chorionic Gonadotropin on Terminal End Buds, Intraductal Proliferations, and Ductal Carcinomas In Situ . . . . .    | 397 |
| 10.5.4 | Effect of Human Chorionic Gonadotropin Treatment on DMBA-Induced Tumor Progression . . . . .  | 398 |
| 10.6   | Effect of Human Chorionic Gonadotropin on Inhibin Expression and Its Relation with the Activation of Early Response Genes . . . . . | 399 |
| 10.7   | Effect of Human Chorionic Gonadotropin on Programmed Cell Death Gene Expression . . . . .   | 404 |
| 10.7.1 | Effect of Human Chorionic Gonadotropin in the Mammary Gland of Animals Treated with DMBA . . . . .                                  | 404 |
| 10.7.2 | Effect of Human Chorionic Gonadotropin Treatment on the Expression of Apoptotic Genes in DMBA-Induced Mammary Carcinomas . . . . .  | 408 |
| 10.7.3 | Effect of Human Chorionic Gonadotropin Treatment on the Expression of Apoptotic Genes in the Ovary . . . . .                        | 408 |
| 10.7.4 | Effect of Human Chorionic Gonadotropin Treatment on Apoptosis . . . . .   | 410 |
| 10.8   | Evidence of a Direct Effect of Human Chorionic Gonadotropin in Mammary Epithelial Cells . . . . .                                   | 411 |
| 10.8.1 | Human Chorionic Gonadotropin Has an Inhibitory Effect on DMBA Mammary Carcinogenesis in Ovariectomized Animals . . . . .            | 411 |
| 10.8.2 | Effect of Human Chorionic Gonadotropin in Human Breast Epithelial Cells In Vitro . . . . .  | 412 |

|           |  |     |
|-----------|--|-----|
| 10.9      | Tumoristatic Effect of Human Chorionic Gonadotropin on Malignant Human Breast Epithelial Cells Transplanted in Heterologous Host . . . . . | 417 |
| 10.10     | Effect of Recombinant Human Chorionic Gonadotropin on Primary Breast Cancer . . . . .  | 417 |
| 10.11     | Isolation and Characterization of New Genes Induced by Human Chorionic Gonadotropin . . . . .  | 419 |
| 10.11.1   | Genes Induced by Human Chorionic Gonadotropin in Human Breast Epithelial Cells In Vitro . . . . .  | 419 |
| 10.11.2   | Genes Induced by Human Chorionic Gonadotropin in the Rat Mammary Gland . . . . .   | 423 |
| 10.11.2.1 | Morphological Phenotypes Induced by Urinary and Recombinant Human Chorionic Gonadotropin . . . . .   | 426 |
| 10.11.2.2 | Differential Display and Northern Blot Analysis . . . . .  | 426 |
| 10.12     | Genomic Signature Induced by Human Chorionic Gonadotropin and Pregnancy . . . . .  | 430 |
| 10.13     | Unifying Concepts . . . . .  | 432 |
|           | References . . . . .   | 433 |

---

|                                |     |
|--------------------------------|-----|
| <b>Subject Index</b> . . . . . | 439 |
|--------------------------------|-----|